RT Journal Article
SR Electronic
T1 Epirubicin and Cyclophosphamide Followed by Docetaxel as Primary Systemic Chemotherapy in Locally Advanced Breast Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4137
OP 4142
VO 28
IS 6B
A1 HIRANO, AKIRA
A1 SHIMIZU, TADAO
A1 WATANABE, OSAMU
A1 KINOSHITA, JUN
A1 KIMURA, KIYOMI
A1 KAMIMURA, MARI
A1 DOMOTO, KAORU
A1 AIBA, MOTOHIKO
A1 OGAWA, KENJI
YR 2008
UL http://ar.iiarjournals.org/content/28/6B/4137.abstract
AB Background: The aim of this study was to evaluate the activity and toxicity of epirubicin and cyclophosphamide (EC) followed by docetaxel as primary systemic chemotherapy (PST) in locally advanced breast cancer. Patients and Methods: In this phase II trial, 46 patients with locally advanced breast cancer (T>3 cm or N>1) received epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks for four cycles, followed by docetaxel (70 mg/m2) every 3 weeks for four cycles. Primary endpoints were pathological and objective response in the breast and axilla, and toxicities. Results: The clinical response rate was 80.4% (95% confidence interval, 68.9-91.9%). Pathological response evaluation revealed 6 complete responses (CR: 13.0%). Patients with ER-negative tumors had a significantly higher rate of pathological CR than the others (33.3% vs. 3.2%; p=0.0105). Febrile neutropenia occurred in 4 patients (8.7%). Conclusion: EC followed by docetaxel is an active and well-tolerated treatment as PST for locally advanced breast cancer. Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved